SLC5A3 and Alzheimer disease: The findings of this study suggest that the beneficial effects seen in the preclinical studies on the efficacy of scyllo-inositol in a Tg mouse model of AD can be attributed to the expression of the SMIT1/2 transporters in brain regions susceptible to AD pathology and the steady transport of scyllo-inositol to those regions to target AD pathology.